This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Edward Van Den Brink, PhD
Director, Antibody Discovery at Genmab


Dr. van den Brink has a wide experience in the discovery, characterization and development of therapeutic antibodies in various disease areas. After completion of his PhD at Sanquin/University of Amsterdam in 2000 and a postdoctoral fellowship at American Red Cross, he continued his career in the biopharmaceutical industry. First at Crucell, now Janssen Vaccines, where he was involved in the discovery of neutralizing antibodies against emerging viruses including SARS-CoV-1 and avian influenza. In his current role as Director Antibody Discovery at Genmab, he is responsible for the generation and characterization of target specific antibody panels. By combining these panels with Genmab’s proprietary antibody format, novel product concepts are created that form the basis for further drug development.

Agenda Sessions

  • Workshop Co-Moderator’s Remarks

  • Antibody Discovery: What Does it Take to Generate the Antibodies Against Your Target of Interest?